LM-306 / Sino Biopharm - LARVOL DELTA

Pre-clinical evaluation of a novel antibody drug conjugate (ADC) LM-306 targeting IL-13Rα2 in immuno-oncology (AACR 2023) - "The highest non-severely toxic dose of LM-306 was determined to be 9 mg/kg in the DRF study and MTD was determined to be 18mg/kg in MTD study for male monkey. In summary, LM-306 showed high binding affinity to human IL13Rα2 expressing cells with potent cytotoxicity in vitro and significant in vivo inhibition of tumor growth, suggesting its therapeutic benefit in immuno-oncology.Summary of parameters of LM-106 and LM-306 binding affinity, internalization, ADCC and cytotoxicityAssayAntibody EC50 (nM)HEK293/H_IL-13Rα2U251A375SKMEL5Binding affinityLM-1060.990.210.570.1LM-3061.470.330.80.12InternalizationLM-1062.22-0.43-ADCCLM-1060.16-0.03-LM-3060.31-0.03-Cytotoxicity (IC50)LM-3060.030.050.010.005"

Immuno-oncology • Preclinical • Brain Cancer • CNS Tumor • Glioma • Melanoma • Oncology • Solid Tumor • IL13 • IL13RA2